The Double Marker Test is an important non-invasive blood test performed during the first trimester of pregnancy, typically between the 9th and 13th weeks. It measures two key hormones in the mother’s blood — Free Beta-hCG and PAPP-A (Pregnancy-Associated Plasma Protein A) — to evaluate the risk of chromosomal abnormalities like Down syndrome (Trisomy 21) and Edwards syndrome (Trisomy 18) in the developing fetus. Often paired with a Nuchal Translucency (NT) scan, this test provides a more accurate early risk assessment. While it does not diagnose any condition, it helps healthcare providers decide whether further testing, such as NIPT or amniocentesis, is necessary. The Double Marker Test is a safe and essential step in modern prenatal care, offering valuable insights to support early and informed pregnancy management.